Abstract: A polyfunctional radical scavenger hydrogel formulation providing extended protection of the extracellular space within a wound site. The polyfunctional radical scavenger hydrogel formulation is generally formed from a hydrogel, a first radical scavenger and a second radical scavenger differing from the first radical scavenger with respect to at least one property. A portion of the first radical scavenger included with the formation and/or second radical scavenger included within the formulation may be dissolved, suspended and/or bonded to a polymer of the hydrogel.

Abstract: The present invention relates to a controlled release oral formulation comprising about 400 mg to about 800 mg of flavoxate salt as an active ingredient, suitable polymers, binders, and excipients, and lacking an acidifying agent. The present invention also provides a method of preparing the controlled release oral formulation of about 400 mg to 800 mg of flavoxate salt. The controlled release formulation of present invention may comprise micronized particles of drug. The controlled release formulation has a controlled release profile of up to 24 hours, that is pH independent, and that is alcohol dose dumping risk-free.

Abstract: The invention provides formulations for oral delivery of a therapeutic agent wherein the formulation comprises a kappa opioid receptor agonist, an oligosaccharide stabilizing agent and an optional absorption enhancer. The kappa opioid receptor agonist may be coated with, embedded in or mixed with an oligosaccharide, such as trehalose. Also provided are capsules containing the oral formulations of the kappa opioid receptor agonists, the oligosaccharide and the absorption enhancer of the invention. The invention further provides methods of manufacture of the formulations and methods of their use for the prophylaxis, inhibition and treatment of variety of kappa opioid receptor-associated diseases and conditions such as pain, pruritus and inflammation. The methods of use include administering to the mammal the formulation of the kappa opioid receptor agonist, oligosaccharide and optional absorption enhancers.

Abstract: A process prepares a polymer-coated hard shell capsule, suitable as container for pharmaceutical or nutraceutical biologically active ingredients. The hard shell capsule can include a body and a cap. In the closed state, the cap overlaps the body either in a pre-locked state or in a final-locked state. The hard shell capsule can be provided in the pre-locked state and spray-coated with a coating solution, suspension, or dispersion that includes a polymer or a mixture of polymers to create a coating layer which covers the outer surface of the hard shell capsule in the pre-locked state.

Abstract: Certain embodiments of the present disclosure provide liquid pharmaceutical formulations, suitable for oral administration, that contain an amount of a tafamidis of from 0.5 mg/ml to 20 mg/ml, water, and an amount of an alkaline pH modifier that yields a content of the tafamidis solubilized in the water of from 0.5 mg/ml to 19.8 mg/ml.

Abstract: The invention relates to a system (10) for dispensing a product, comprising a dispenser that can house at least two cartridges, each of which includes a reservoir containing a base product, a first base product comprising at least 0.1 wt.-% particles having a density differential relative to the medium containing same, preferably of at least 0.5 g/cm3, in particular particles having a density greater than or equal to 2 g/cm3, and a thickening agent. The dispenser allows at least two base products to be dispensed in adjustable proportions, the viscosity of the first base product being preferably greater than 2 Pa·s and more preferably greater than or equal to 4 Pa·s.

Abstract: The invention relates to a system (10) for dispensing a product, comprising a dispenser that can house at least two cartridges, each of which includes a reservoir containing a base product, a first base product comprising at least 0.1 wt.-% particles having a density differential relative to the medium containing same, preferably of at least 0.5 g/cm3, in particular particles having a density greater than or equal to 2 g/cm3, and a thickening agent. The dispenser allows at least two base products to be dispensed in adjustable proportions, the viscosity of the first base product being preferably greater than 2 Pa·s and more preferably greater than or equal to 4 Pa·s.

Abstract: The present invention relates to an ethanol foam sclerosing agent for vascular anomalies and a preparation method thereof. The ethanol foam sclerosing agent includes absolute ethanol, water, Tween 80 and a stabilizer. The ethanol foam sclerosing agent further includes hyaluronic acid. The mass composition of the ethanol foam sclerosing agent includes 32-42% of absolute ethanol, 0.5-2% of Tween 80, 0-25% (excluding 0) of egg yolk lecithin, 0-2% (excluding 0) of hyaluronic acid, and the balance of water. The stabilizer is hyaluronic acid or glycerin. Foam is prepared by the Tessari method. While the original therapeutic effect of ethanol is not changed, the side effect of the ethanol is significantly reduced.

Abstract: Compositions for treating inflammatory skin conditions are described. The compositions can include povidone iodine in aqueous solution, hydrocortisone, diphenhydramine, an emulsifier, and a hydrophobic carrier, where the povidone iodine aqueous solution is emulsified in the hydrophobic carrier. A method of preparing a composition is also described. The method can include adding an aqueous solution of povidone iodine to a hydrophobic carrier, and adding an emulsifier to the hydrophobic carrier at a concentration that emulsifies the aqueous solution of povidone iodine in the hydrophobic carrier upon mixing.

Abstract: The present invention provides compositions, systems, kits, and methods for preparation prior to a colonoscopy or other gastrointestinal procedure. In particular, the present invention provides a colon lavage system comprising an aqueous portion and a solid portion.

Abstract: The present invention relates to pharmaceutical compositions comprising Akt protein kinase inhibitors with therapeutic activity against diseases such as cancer as well as processes for their preparation and their use as medicament.

Abstract: Formulations of tegavivint, methods of making such formulations, and methods of treatment of cancer by administering the formulations.

Abstract: Embodiments provide a pest control agent that is excellent in safety, controlling effect, residual activity, and so on. According to an embodiment, there is provided a pyrazole derivative represented by general formula [I], or an agriculturally acceptable salt thereof, and a pest control agent containing the same as an active ingredient: wherein, p represents an integer of 0 or 1, R1, R2, R3, R4, and R5 represent a hydrogen atom, halogen atom, C1-C6 alkyl group, or the like, A represents an oxygen atom or sulfur atom, Q represents a halogen atom, C6-C10 aryl group that is unsubstituted or substituted with (R8)m, or the like, and R6 and R7 represent a hydrogen atom, C1-C6 alkyl group, or the like.

Abstract: The present invention provides a nanoparticle comprising a poly(alkyl cyanoacrylate) homopolymer, or copolymer, at least one active agent and an anionic and radical inhibitor, wherein the anionic and radical inhibitor is a compound having the following formula: wherein R1 is H; and R3, R4, R5, R6 and R7 are independently selected from the group consisting of —H, —OH, C1-C6 alkoxide, C1-C6 alkyl, halides, carboxylic acid, ketone or aldehyde; wherein the anionic and radical inhibitor is present in an amount of 0.001 to 15 wt %, as well as a process suitable for manufacture of the nanoparticle.

Abstract: Disclosed is a pharmaceutically-acceptable composition in the form of a solid, amorphous, mono-particulate powder comprising a mixture of: (a) a pharmacologically-effective dosage amount of an adrenergic receptor modulator, or a pharmaceutically-acceptable salt thereof; and (b) a pharmaceutically-acceptable carrier material, which carrier material comprises a maltodextrin with a dextrose equivalent (DE) that is above 15. Compositions are suitable for transmucosal drug delivery, including nasal delivery, by which said compositions may be loaded into a single-use nasal applicator. Compositions are preferably made by way of spray drying and may further include a disaccharide, such as lactose or trehalose which, along with the active ingredient and maltodextrin, may be spray-dried together in combination. Compositions may further comprise one or more alkyl saccharides. Preferred alkyl saccharides include sucrose esters, such as sucrose monolaurate.

Abstract: A therapeutic composition and a method of producing it by light-activating hypericin in a carrier or solvent. Preferably, the composition is made by combining dried flowers and/or flower stems of St. John's Wort with edible oil and exposing the mixture to the sun for a prolonged time. This process serves to light-activate the hypericin before its use and reduce risk of skin phototoxicity. The composition can be used for treating undesirable conditions such as mouth sores and vaginal infections.

Abstract: The present disclosure relates to a pharmaceutical composition having a mixture containing curcuminoids as at least one of the active therapeutic agents. Generally, the mixture comprises 4-8% by weight of purified curcuminoids; 20-35% by weight of an oil phase; 25-35% by weight of a co-solvent; and 40-50% by weight of a surfactant. Preferably, the purified curcuminoids in the mixture has an average size of about 19 nm or at least half of the curcuminoids carried in the mixture has particle size not exceeding 19 nm.

Abstract: The present subject matter relates to a stable pesticidal formulation which exhibits improved dispersibility in cold water and full compatibility with fertilizers.

Abstract: Pharmaceutical compositions comprising an immediate release component comprising 4-((L-valyl)oxy)butanoic acid and a modified release component comprising 4-((L-valyl)oxy)butanoic acid and the pharmacokinetics of 4-((L-valyl)oxy)butanoic acid and ?-hydroxybutyrate following oral administration of the pharmaceutical compositions is disclosed.

Abstract: The present application relates to a pregabalin sustained release composition, comprising: (a) an active ingredient; (b) a matrix-forming agent; (c) a swelling agent; (d) a gelling agent; and optionally a filler. The pregabalin sustained release composition provided in the present application can rapidly swell in volume when exposed to aqueous medium until exceeding the dimeter of human gastric pyloric (13 mm). It thereby prolongs the gastric emptying time to increase the retention time of pregabalin in the stomach and enhances absorption of pregabalin in the small intestine and ascending colon. Moreover, the pregabalin sustained release composition provided herein achieves a sustained release for 24 h, which allows QD (once a day) administration, reduces administration number, and improves patient compliance.